Workflow
康弘药业(002773) - 2019 Q3 - 季度财报
KHPGKHPG(SZ:002773)2019-10-30 16:00

Financial Performance - Operating revenue for the reporting period was ¥890,917,081.32, reflecting an increase of 11.48% year-on-year[3]. - Net profit attributable to shareholders was ¥211,987,262.90, representing an 8.06% increase compared to the same period last year[3]. - Basic earnings per share were ¥0.24, up by 9.09% year-on-year[3]. - The net profit for the third quarter of 2019 was CNY 211,987,262.90, an increase from CNY 196,173,056.94 in the same period last year, representing a growth of approximately 8.8%[28]. - The total profit for the quarter was CNY 256,245,391.08, compared to CNY 226,652,796.14 in the previous year, marking an increase of about 13.1%[28]. - Net profit for the current period was ¥552,269,121.81, representing an increase of 9.06% from ¥506,456,695.84 in the previous period[36]. - Basic and diluted earnings per share increased to ¥0.63 from ¥0.58, marking a growth of 8.62%[37]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,507,893,053.46, an increase of 6.03% compared to the end of the previous year[3]. - The company's current assets totaled CNY 3,087,387,024.62, down from CNY 3,412,828,931.88 in the previous year, indicating a decrease of approximately 9.5%[20]. - Total liabilities decreased to CNY 1,052,528,035.25 from CNY 1,110,927,768.65, indicating a decline of approximately 5.2%[21]. - The company's total liabilities were reported at ¥306,224,337.93, a decrease from ¥327,773,747.60 in the previous year[25]. - The total non-current assets increased to CNY 2,420,506,028.84 from CNY 1,782,053,325.47, marking an increase of approximately 35.9%[20]. - The company reported a total of CNY 588,450,297.30 in current liabilities, a decrease from CNY 619,968,077.61, indicating a reduction of about 5.1%[21]. Cash Flow - The net cash flow from operating activities surged by 354.51% to ¥298,508,259.17 during the reporting period[3]. - Net cash flow from operating activities increased by 161.73% year-on-year, mainly due to an increase in sales receipts during the reporting period[11]. - Cash inflow from operating activities reached CNY 2,642,901,847.60, up from CNY 2,213,931,344.10 in the prior period, reflecting a growth of approximately 19.4%[43]. - The net cash flow from operating activities was CNY 537,694,549.68, significantly higher than CNY 205,437,457.68 in the previous year, marking an increase of about 161.5%[43]. - The cash flow from investment activities resulted in a net outflow of CNY 789,780,131.01, an improvement from the previous net outflow of CNY 1,163,528,865.95[44]. - The net cash flow from financing activities was negative CNY 229,186,018.41, worsening from a negative CNY 193,507,731.14 in the previous period[44]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,461[6]. - The largest shareholder, Chengdu Kanghong Technology Industry (Group) Co., Ltd., held 33.35% of the shares[6]. - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[7]. Expenses - Operating expenses increased by 102.04% year-on-year, mainly due to an increase in charitable donations during the reporting period[10]. - Financial expenses increased by 37.08% compared to the same period last year, mainly due to a decrease in interest income and exchange rate fluctuations[10]. - Research and development expenses increased to ¥87,574,093.66, compared to ¥63,778,560.19 in the previous year, marking a growth of 37.3%[27]. - The company's sales expenses were ¥1,191,589,949.37, slightly up from ¥1,136,025,229.00, reflecting a 4.91% increase[35]. Government Support - The company received government subsidies amounting to ¥59,215,778.81 during the reporting period[4]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[36].